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Health Care Funding and Provision of the Republic of Srpska
Health Care Services in the Republic of Srpska are provided through the primary, secondary, and
tertiary care levels. Primary medical services provision happens throughout the network of 53
primary health care facilities and 1 family medicine polyclinic (1). There are approximately 500
pharmacies (2). Secondary and tertiary health care services are provided in two university hospitals,
nine regional hospitals, three health centers, two specialized psychiatric clinics, and two specialized
medical rehabilitation facilities (3). Insured citizens use health care services in public health care
institutions and private institutions who have signed the contract with the Health Insurance Fund.
Health care financing is mostly provided by the Health Insurance Fund, out of the mandatory taxes
imposed to the employers and employees alike. Coverage for unemployed population is extended
from the employed family member premiums (4). Fund is a legal entity established and owned by
the State (5). The Ministry of Health and Social Welfare conducts the supervision of the Fund (6).
One of the main functions of the Health Insurance Fund is collection of contributions for health
insurance and contracting of health services. Complementary direct payment of contributions is
made to the Pension and Disability Insurance Fund (7). The health care system in the Republic of
Srpska is centralized with the overall power trusted to the Ministry of Health and Social Welfare,
the Institute of Public Health, and the Health Insurance Fund. Employee pool in the health care
system of the Republic of Srpska consists of approximately 2,400 clinical physicians, 200 dentists,
100 pharmacists, 6,500 nursing staff, and 4,000 administrative and technical staff (1). Gross National
Income per capita increased from 8,770 to 9,820 US$ during 2009–2013 span. Total expenditure on
health, as a percentage of gross domestic product, was 9.9% in 2012 (last official release) (8). The
Republic of Srpska has around a population of 1,327,000 (9), and health expenditure per capita in
2009 amounted toAC389while in 2013 it reachedAC397 (10). Private and public expenditure on health
care has increased in total from 2009 to 2012, and the public share of spending grew from 68.81 to
70.33% (11).
Official Records on Prescription Medicines
The Agency for Medicinal Products and Medical Devices of Bosnia and Herzegovina issues annual
reports on utilization of pharmaceuticals nationwide. These annual reports are commercially
available since 2009 (12). This source contains data onmedicines prescription, dispensing, and sales
provided directly by the pharmaceutical multinationals and domestic manufacturers. Wholesalers
are required to provide data on the number of packages of drugs that are imported and wholesale
price. This price usually consists of manufacturer’s price plus customs, incremental costs, and the
wholesale markup. Domestic producers were required to provide data on the number of packages of
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drugs that are produced and released into the market with whole-
sale price (manufacturer’s price plus the wholesale markup).
Costs are expressed in Bosnia and Herzegovina’s local currency –
convertible mark (BAM). Data are ordered in ATC (Anatomi-
cal–Therapeutical–Chemical) codes on first, second, third, fourth,
and fifth level of classification (13). Latest report has been made
in 2014 for the year 2013. Total of 39 wholesalers provided data.
The ratio of domestic and foreign manufacturers of medicines
in the total turnover of pharmaceuticals in 2013 was 17 vs. 83%
(14). Population health official estimate is being issued annually
by the Public Health Institute of the Republic of Srpska (15). It
provides us with exact data with regard to health facilities, staffing,
and the structure of spending (public and private expenditure).
Third source of data supporting these claims was the Agency for
Statistics’ publications on gross domestic product and National
Health Accounts Statistics for the period from 2009 to 2013 (16).
Ongoing Pharmaceutical Market
Transformation 2009–2013
Observing 5-year time horizon (2009–2013), we see thatmoderate
growth of pharmaceutical market took place. Some ATC code
groups recorded far more substantial market changes than others.
Thus, systemic hormonal preparations, excluding sex hormones,
and insulin value-based turnover increased for 92%, and antipar-
asitic products, insecticides, and repellents spending decreased
for 63%. Changes were also significant in the indication field
of blood and blood-forming organs reporting 36% growth, as
well as antineoplastic and immunomodulating agents, sensory
organs, respiratory system, and alimentary tract and metabolism
drugs which increased their sales volume around 30% each. Top
10 ATC second-level code groups in 2009 and 2013 have been
renin–angiotensin system agents, antibacterials for systemic use,
antineoplastic agents, psycholeptics, drugs used in diabetes, drugs
for acid-related disorders, analgesics, calcium channel blockers,
anti-inflammatory and antirheumatic products, beta blocking
agent, and antithrombotic agents. Consumption of preparations
for wounds and ulcers treatment has increased three times.
Nasal preparations, digestives, including enzymes, pituitary and
hypothalamic hormones, and prescribing antigout preparations
have also increased twofold (Table 1).
Differences in certain ATC drug group consumption are
reflecting the changes that have been happening in the national
health system. Prices have been reduced, especially for generic
drugs where patent protection has expired. A lot of effort has been
invested in the implementation of good clinical practice guide-
lines. That is the reason for reducing antibiotics consumption out-
sourcing from decreased frequency of nosocomial infections and
overprescribing by general practice physicians. Development of
novel targeted antineoplastic medicines, primarily the biologicals,
as well as increased incidence of malignant diseases influenced
constant growth of utilization. The level of obesity is increasing
and so is antidiabetics consumption as well as pharmaceuticals
indicated in cardiovascular and associated diseases.
TABLE 1 | Top 10 ATC second- and third-level drug code groups ranked in 2009 and 2013 according to value-based turnover of dispensed medicines and
its growth ratio 2013/2009a.
Top 10 ATC second-level code groups in 2009
and 2013 (hierarchy from 2009 applied
in descending order of appearance)
Value of prescriptions
dispensed in 2009
(million AC)
Value of prescriptions
dispensed in 2013
(million AC)
Growth ratio
2013/2009
Total increase
2009–2013 (million AC)
C09 agents acting on the renin–angiotensin system 25.9 26.8 1.03 0.9
J01 antibacterials for systemic use 21.8 16.2 0.74 5.6
L01 antineoplastic agents 16.1 21.4 1.33 5.3
N05 psycholeptics 13 10.1 0.78 2.9
A10 drugs used in diabetes 12.5 23.1 1.85 10.6
A02 drugs for acid-related disorders 10.5 10.3 0.98 0.2
N02 analgesics 9.6 9.1 0.95 0.5
C08 calcium channel blockers 7.4 5.4 0.73 2
M01 anti-inflammatory and antirheumatic products 7.4 8.9 1.21 1.5
C07 beta blocking agent 6.9 8.1 1.18 1.2
B01 antithrombotic agents 6.8 10.6 1.56 3.8
Top 10 ATC third-level code groups
according to 2013/2009 growth ratio
Value of prescriptions
dispensed in 2009
(thousand AC)
Value of prescriptions
dispensed in 2013
(thousand AC)
Growth ratio
2013/2009
Total increase
2009–2013 (thousand AC)
C01C cardiac stimulants excluding cardiac glycosides 7.6 122 16.07 114.5
S03A anti-infectives 3.8 36 9.47 32.2
M03A muscle relaxants, peripherally acting agents 37.1 347.6 9.37 310.5
C09D angiotensin II antagonists, combinations 511 2993.1 5.86 2482.1
S01B Anti-inflammatory agents 17.8 99.5 5.59 81.7
R01B nasal decongestants for systemic use 484.6 2350.1 4.85 1865.5
D03A cicatrizants 43.3 169 3.90 125.7
L01A alkylating agents 238.6 876.8 3.67 638.2
V03A all other therapeutic products 53 189.2 3.57 136.2
G02B contraceptives for topical use 19.9 70.5 3.54 50.6
aLatest Republic of Srpska’s official release available [publicly reimbursed prescription medicines only; over-the-counter (OTC) and out-of-pocket citizen payments excluded].
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Forecasts of Future Changes
Although there are some promising developments, local phar-
maceutical market structure and dynamics is still far from the
one responsive to population needs. In the country still recov-
ering from unstable political situation over the last few decades,
a lot of progress has been made. The Health Insurance Fund is
consistently negotiating with pharmaceutical companies impos-
ing price caps and generic substitution wherever possible. Thus,
Fund created more room for innovative therapies reimbursement.
That is why authorities are considering marketing approvals of
novel drugs indicated in hepatitis, diabetes, targeted antineoplas-
tic agents (17), as well as immunotherapy, which we expect to be
available to the patients over the next 5–10 years.
Western Balkan countries share post-socialist legacy of former
Yugoslavia in health care management and financing patterns
(18). Quite similar but faster development in a large-scale popu-
lation could be observed in neighboring Serbia (19). This country
suffered as well from seriously constrained resource allocation
for medicines during global economic recession (20). Signs of
early recovery are now clearly present particularly in the oncol-
ogy indication field (21). Accessibility and affordability of inno-
vative therapies gradually became reality for even the poorest
citizens (22).
The Republic of Srpska due to its smaller population size
might have more convenient opportunity for sustainable health
policy solutions learning from painful lessons of other South-East
European transitional health reforms (23). Current developments
nationwide present a promise of more responsive pharmaceutical
market. The country is likely to be capable of providing more
affordable, mostly generic medicines in the upcoming years.
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